CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled / 33 target
Drug / intervention
MPC closed-loop system in insulin only mode +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06422325
NCT06422325N/ACompletedOn Track (1.4/mo)Completion was 17mo ago

A Crossover Study to Evaluate Insulin/Pramlintide Versus Insulin Alone Delivery Strategy

Oregon Health and Science University·interventional·Posted May 20, 2024·Updated Jun 9, 2026

In Brief

A clinical study evaluating MPC closed-loop system in insulin only mode and MPC closed-loop system in insulin/pramlintide mode for Type 1 Diabetes. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to test how well a new investigational closed loop system manages your blood sugar with the ability to deliver insulin and pramlintide. Pramlintide is a drug that is used with mealtime insulin to control blood sugar in people who have diabetes. It works by slowing down the movement of food through the stomach which prevents blood sugar from rising too high after a meal. The closed loop system will receive glucose values from the Dexcom G6 continuous glucose monitoring (CGM) and automatically send commands to one Omnipod for insulin and one Omnipod for pramlintide delivery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States

Timeline

N/ACompletedFinished
20252026
First PostedMay 20, 2024
Enrollment StartJul 12, 2024
Primary CompletionJan 4, 2025
Study CompletionJan 28, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.1 years ago

Arms & Interventions

Insulin Only Armexperimental

Participants will use the closed loop system with insulin only for managing blood sugar during the 12.5 hour study. Insulin will be administered by an Omnipod. Sensor glucose will be measured by a Dexcom G6 CGM. Participants will eat two meals while in clinic.

Device: MPC closed-loop system in insulin only mode
Insulin and Pramlintide Armexperimental

Participants will use the closed loop system with insulin and pramlintide for managing blood sugar during the 12.5 hour study. Insulin and pramlintide will be administered by two Omnipods. Sensor glucose will be measured by a Dexcom G6 CGM. Participants will eat two meals while in clinic.

Device: MPC closed-loop system in insulin/pramlintide mode

Interventions

MPC closed-loop system in insulin only modedevice

The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.

MPC closed-loop system in insulin/pramlintide modedevice

The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.